BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Cisplatin
,
rs4950928
,
EGFR
,
Coagulation
,
Influenza
,
Endothelial cell
,
Amniocentesis
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
vla 4
Summary
General Info
Curated Studies
Most Correlated Studies
B-cell acute lymphoblastic leukemia REH cells co-cultured with bone marrow mesenchymal stromal cells
Bone-marrow mesenchymal stromal cells from multiple myeloma patients and healthy donors
B-lymphocyte subset responses to LPS induced sepsis
Lungs from mice injection with melanoma B16-F10 exosome protein
Explore Curated Studies Results
Literature
Most Relevant Literature
ATG8 inhibited endometriosis formation by regulating Treg cells differentiation via integrin α4β1 an…
Leishmania amazonensis infection impairs VLA-4 clustering and adhesion complex assembly at the adhes…
VLA-4 as a Central Target for Modulating Neuroinflammatory Disorders.
Design and Pharmacological Characterization of α4β1 Integrin Cyclopeptide Agonists: Computational In…
An Overview of the α4β1 Integrin and the Potential Therapeutic Role of its Antagonists.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Levels of Circulating T Cells Expressing VLA-1 Collagen Receptors
A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-00…
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 C…
Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ